secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-07-24T23:59:59+00:00
Accession:  0001437749-25-023351
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia submits CardiAMP cell therapy for PMDA clinical consultation in Japan
-------------------------------------------------------------------------------

- Submitted clinical data package including full CardiAMP HF trial results and STED to Japan's PMDA on July 24, 2025.
- Consultation seeks PMDA alignment on efficacy, safety, target patient population, and positioning in heart failure care.
- Positive PMDA feedback could enable BioCardia to submit for market approval in Japan.
- CEO expects potential post-marketing study in Japan next year if regulatory pathway is cleared.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925023351/0001437749-25-023351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925023351/bcda20250723_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-023351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer